title: Chemotherapy for advanced gastric cancer: review and update of current practices.
abstract: No standard adjuvant or palliative chemotherapy regimen has been internationally approved for patients with advanced gastric cancer. Adjuvant chemoradiotherapy is administered prior to surgery and is used in the Unitied States, and intensified chemotherapy is administered prior to and after surgery and is used in Europe. Limited D1 dissections are also frequently performed in the United States and Europe. In Korea, patients undergoing D2 resection appear to benefit from postoperative adjuvant chemotherapy using S-1 or capecitabine plus oxaliplatin. Fluoropyrimidine, platinum, taxane, epirubicin, and irinotecan may be employed alone or in combination as a first-line therapy in a palliative chemotherapy regimen. In Asia, an orally administered fluoropyrimidine, such as capecitabine or S-1, is favored over the continuous infusion of 5-fluorouracil because of its convenience. Trastuzumab has been integrated into the current standard chemotherapy for human epidermal growth factor receptor 2-overexpressing gastric cancers. There is currently no standard regimen for secondary palliative chemotherapy. Clinical studies of several targeted therapies are ongoing.
authors.affiliation: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, Korea.
authors.forename: Sung Chul
authors.initials: SC
authors.lastname: Park
authors.forename: Hoon Jai
authors.initials: HJ
authors.lastname: Chun
keywords: Drug therapy; Stomach neoplasms
references.citation: Lancet. 2010 Aug 28;376(9742):687-97
references.pmid: 20728210
references.citation: J Clin Oncol. 2006 Jun 20;24(18):2903-9
references.pmid: 16782930
references.citation: J Clin Oncol. 2012 Jan 20;30(3):268-73
references.pmid: 22184384
references.citation: N Engl J Med. 2008 Jan 3;358(1):36-46
references.pmid: 18172173
references.citation: Acta Oncol. 2001;40(2-3):309-26
references.pmid: 11441938
references.citation: Lancet. 2012 Jan 28;379(9813):315-21
references.pmid: 22226517
references.citation: JAMA. 2010 May 5;303(17):1729-37
references.pmid: 20442389
references.citation: J Clin Oncol. 2006 May 10;24(14):2188-96
references.pmid: 16682738
references.citation: Ann Oncol. 2000 Jul;11(7):837-43
references.pmid: 10997811
references.citation: Eur J Cancer. 2011 Oct;47(15):2306-14
references.pmid: 21742485
references.citation: Lancet Oncol. 2010 May;11(5):439-49
references.pmid: 20409751
references.citation: Cancer Res Treat. 2012 Mar;44(1):11-24
references.pmid: 22500156
references.citation: Br J Surg. 2003 Sep;90(9):1113-9
references.pmid: 12945079
references.citation: J Clin Oncol. 2008 May 1;26(13):2118-23
references.pmid: 18445840
references.citation: Ann Surg Oncol. 2007 Oct;14(10):2702-13
references.pmid: 17653801
references.citation: J Clin Oncol. 2012 Jun 10;30(17):2119-27
references.pmid: 22565005
references.citation: Cochrane Database Syst Rev. 2010 Mar 17;(3):CD004064
references.pmid: 20238327
references.citation: J Clin Oncol. 2012 May 1;30(13):1513-8
references.pmid: 22412140
references.citation: J Clin Oncol. 2011 May 1;29(13):1715-21
references.pmid: 21444866
references.citation: Ann Oncol. 2015 Jan;26(1):149-156
references.pmid: 25416687
references.citation: Ann Surg. 2010 Apr;251(4):640-6
references.pmid: 20224369
references.citation: Ann Oncol. 2009 Apr;20(4):666-73
references.pmid: 19153121
references.citation: N Engl J Med. 2001 Sep 6;345(10):725-30
references.pmid: 11547741
references.citation: Ann Oncol. 2013 Jul;24(7):1754-1761
references.pmid: 23524864
references.citation: Ann Oncol. 2008 Aug;19(8):1450-1457
references.pmid: 18558665
references.citation: J Clin Oncol. 2011 Nov 20;29(33):4387-93
references.pmid: 22010012
references.citation: Cancer Sci. 2013 Jan;104(1):116-23
references.pmid: 23066919
references.citation: N Engl J Med. 2006 Jul 6;355(1):11-20
references.pmid: 16822992
references.citation: J Clin Oncol. 2008 Mar 20;26(9):1435-42
references.pmid: 18349393
references.citation: J Clin Oncol. 2006 Nov 1;24(31):4991-7
references.pmid: 17075117
references.citation: J Clin Oncol. 2011 Oct 20;29(30):3968-76
references.pmid: 21844504
references.citation: Lancet Oncol. 2008 Mar;9(3):215-21
references.pmid: 18282805
references.citation: Ann Oncol. 2008 Sep;19(9):1523-9
references.pmid: 18441328
references.citation: Lancet Oncol. 2010 Jan;11(1):75-84
references.pmid: 20129130
references.citation: Ann Oncol. 2009 Sep;20(9):1529-1534
references.pmid: 19474114
references.citation: J Clin Oncol. 1997 Jan;15(1):261-7
references.pmid: 8996151